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Summary: Ninety-seven fixed surgical thyroid specimens and 63 unfixed and 40 fixed thyroid specimens from
autopsies were examined for their oxalate content. Proteases were used to process the tissue, and the oxalate
was determined with an enzymatic assay. The fixed samples were grouped into seven diagnostic categories
(diffuse colloid goitre; partially diffuse, partially nodular colloid goitre; nodular colloid goitre; goitre with
multifocal functional autonomy; non-functioning adenoma; unifocal functional autonomy; Graves' disease).
The oxalate concentrations of the samples were mainly dependent on age and gender, which were distributed
unequally among the seven diagnostic groups. In thyroid tissue from cases of Graves' disease, however, the
concentration of oxalate was remarkably low and statistically different from those of four of the six other
groups.
Introduction
Dietary intake contributes only a minor proportion
of the oxalate in humans. More than 80% of oxalate
is derived from metabolism, in particular of glycine
and ascorbic acid (1). A small amount is also synthe-
sized from glycolic acid, hydroxyproline, tryptophan
(2), and possibly also from purines (3). The intestinal
flora may also play a role (4).
Microscopic and macroscopic calcium oxalate crystals
are deposited in organs such as the kidneys, thymus,
vessel walls, the prostate, testicles, brain, eyes, and in
granulation tissue (5 — 15). Calcium oxalate exists in
three hydration states in the organism: monohydrate
(whewellite), dihydrate (weddellite) and trihydrate,
the monohydrate being the least soluble (16). As a
rule, the calcium oxalate deposits are only found in
injured tissue or in pathological states (17).
Calcium oxalate deposits in the colloid of thyroid
follicles were first discovered by Krause in 1868 (18);
using X-ray diffraction, Richter & McCarty (8) iden-
tified this calcium oxalate as the monohydrate. Ac-
cording to MacMahon et al. (17) the distribution of
calcium oxalate crystals in the thyroid is not homog-
enous. Prolonged storage of bulk thyroid tissue in
either acid formaldehyde (for two weeks) or in buf-
fered formaldehyde (over six months) has no obvious
effect on the number of oxalate crystals, i. e., crystals
are not lost during this fixation in contrast to other
fixation methods (19, 20).
Previous morphological studies have documented that
oxalate can be found in crystal form in the thyroid.
The current work seeks to establish a system for
quantifying the amount of oxalate present, and to
correlate this with morphological and functional
quantities by using histological and scintigraphical
methods. To the authors' knowledge, there have been
no data published to date on this subject. The results
of this study might be used as a basis for further
research on the pathophysiological properties of ox-
alate.
Materials and Methods
Ninety-seven surgical specimens fixed in 4% formaldehyde were
examined. The thyroid tissue came from the Tübingen-Stuttgart
area in Southern Germany, where goitres are endemic.
The diagnostic categories used are based upon histological
findings which do not entirely correspond to WHO nomencla-
ture. Any remarkable scintigraphic findings were also taken
into account, especially since hot nodules cannot be easily
identified histologically. Histologically and scintigraphically
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'normal' thyroids were not available for this study. Treatment
of patients was ignored because thyroid diseases have in general
a long history.
Classification of diagnostic groups:
1. Diffuse colloid goitre
2. partially diffuse, partially nodular colloid goitre
3. Nodular colloid goitre
4. Goitre with multifocal functional autonomy (based on his-
tological findings)
5. Non-functioning adenoma (cold nodule)
6. Unifocal functional autonomy (hot nodule)
7. Graves' disease
Tissue specimens were processed within one month after their
receipt. Unfixed thyroid glands were stored at -20°C, and
then thawed for further processing. Unfixed as well as fixed
glands were ground in an electric blender. The tissue was then
placed in plastic bags and flattened manually, frozen at —20 °C,
then crushed into small pieces with a hammer. These were
subsequently, pulverized with a mortar and pestle in liquid
nitrogen. About 5 g of this material were used for further
processing. The quantity of oxalate was measured with an
enzymatic test system (Sigma Diagnostics, Deisenhofen, Ger-
many, catalog No. 590).
Two separate pilot measurements showed that formaldehyde
concentrations as applied to the fixation of tissue clearly inhib-
ited the enzymatic oxalate determination, whereas in the con-
centration range of about 50 mg/1 or lower formaldehyde did
not interfere. Formaldehyde was therefore removed from the
tissue preparation before analysis, using a method that did not
also remove oxalate. Calcium chloride was chosen for this
purpose, because calcium forms insoluble calcium oxalate com-
plexes with free oxalate ions. The calcium chloride was dissolved
in 99.9% ethanol rather than in water in order to lower the
solubility product of these complexes. When calcium chloride
was dissolved only in water instead of ethanol no precipitates
of calcium oxalate were recognizable.
The tissue specimens were washed twice with 2.5 g/1 and twice
with 5 g/1 CaCl2 in ethanol, each time for two hours. Between
each washing, the samples were centrifuged at approximately
100 £ for 10 minutes and the supernatants discarded. The al-
cohol residues were removed by heating the test tubes at 60 —
70 °C until dry. Oxalate does not decompose at this tempera-
ture. In a pilot measurement the analytical recovery of pure
oxalic acid (100 mg/1), dissolved in 4% formaldehyde and
precipitated with CaCl2-ethanol in the same manner as de-
scribed above, ranged from 92—98%. The mean recovery was
94% (n = 6). Oxalic acid loss in the supernatant was therefore
tolerably constant, small and considered negligible. The Merck-
oquant® formaldehyde test (Merck; Darmstadt, Germany;
measuring range 10 -100 mg/1) did not detect any formaldehyde
after the fourth washing, and the Aquamerck® formaldehyde
test (Merck, Darmstadt, Germany; measuring range 0.1-1.5
mg/1) only detected 0.15 ± 0.44 mg/1 (n = 12).
The alcohol treatment dehydrated the thyroid tissue. This al-
lowed the omission of a lyophilization procedure, which would
otherwise have been required. The next step was the precise
weighing of the dry thyroid material.
The enzymatic oxalate test used was originally designed for the
measurement of oxalate in urine. Consequently, the thyroid
specimens had to be submitted to special preparation proce-
dures. According to Andrews et al. (21) fat can interfere in the
determination of oxalate. The pulverized and dried tissue spec-
imens were therefore treated with pure light petroleum (b.p.
40-60°C, Merck, Darmstadt, Germany), in which oxalate is
insoluble, in order to remove any fat remaining after the alcohol
treatment. The test tubes containing the tissue powder with the
light petroleum were briefly submitted to a vacuum, which was
then released to accomplish tissue saturation. The light petro-
leum with any dissolved fat was discarded and the residues
were evaporated. f
The enzymatic assay for the determination of oxalate must be
performed at an acidic pH. This acid environment causes on
the one hand the dissolution of the calcium oxalate crystals,
but on the other hand, free oxalate binds to protein under the
acidic conditions. Moreover, protein would partially precipitate
in an acid environment. In order to digest the proteins already
denatured by formaldehyde and alcohol, the tissue specimens
were therefore treated with proteolytic enzymes (22) prior to
adding the acid. Five different proteases as well as two nucleases
were used each in a volume of 3 ml.
1. Dispase [EC 3.4.24.4]') (5 g/1 H2O; incubation 16 h, 37 °C)
2. Pepsin [EC 3.4.23.1]1) (2 g/1 0.06 mol/1 HC1; incubation 8 h,
25 °C)
3. Trypsin [EC 3.4.21.4] (2 g/1 0.001 mol/1 HC1; incubation 8 h,
25 °C)
4. Papain [EC 3.4.22.2]1) (2 g/1 0.05 mol/1 phosphate buffered
saline; incubation 16 h, 40 °C)
5. Pronase E [EC 3.4.24.4]1) (3 g/1 0.067 mol/1 phosphate buf-
fered saline; incubation 16 h, 40 °C)
6. DNase and RNase1) (0.003 g/1 H2O and 0.1 g/1 H2O; incu-
bation 8 h, 25 °C)
The dispase (cat. No. 165859) and pepsin (porcine, cat. Nr.
108057) were from Boehringer, Mannheim, Germany, trypsin
(bovine, cat. No. 24579), papain (cat. No. 7144), pronase E
(cat. No. 7433), bovine DNase (cat. No. 16326) and bovine
RNase (cat. No. 24686) were supplied by Merck, Darmstadt,
Germany.
To each litre of protease solution 4ml of a streptomycin-
penicillin concentrate (500000 U/0.5 g in 20 ml; Eurobio, Paris,
France) and l g potassium sorbate were added as preservatives.
Between each proteolytic treatment, the samples were centri-
fuged at 1600 g for 30 minutes and the supernatant was dis-
carded. Oxalate was determined in the protease and nuclease
supernatants of a number of samples. Any protease residue
remaining in the tissue sediment was inactivated by heating the
samples for 15 minutes at 90 °C to avoid interference with the
enzymatic test system. The Albym® dipstick test (Boehringer,
Mannheim, Germany; practical sensitivity limit 60 mg/1), de-
signed for the detection of urinary protein, confirmed that there
were no tissue protein residues left in the samples. The residues
of the protease proteins were not detected by this dipstick
method, but they were detectable by Coomassie-Brilliant-Blue
methods for protein determination. The sediment of thyroid
tissue was subsequently acidified with 2 ml 2 mol/1 HC1. Cal-
cium, which inhibits the oxalate oxidase and therefore the
enzymatic determination of oxalate, was bound with 2 ml so-
dium EDTA (8 g/1).
Sixty-three unfixed samples from autopsies were prepared in a
similar manner and compared with forty fixed samples from
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autopsies could not be determined, because histological and
scintigraphic data were not available for this group. The tissue
of these unfixed samples pulverized in liquid nitrogen was not
dehydrated by ethanol but lyophilized prior to further treat-
ment.
The quantitative enzymatic test used for the determination of
the oxalate content of the thyroid specimens is based on the
oxidation of oxalate by oxalate oxidase, yielding carbon dioxide
and hydrogen peroxide. Hydrogen peroxide is measured by
means of an indamine dye. Maximal absorbance of the inda-
mine dye lay at 592 nm (bandwidth 0.5 nm) as determined with
a Response® spectrophotometer (Gilford, Giessen, Germany).
Absorbance of samples was measured at this wavelength versus
a blank. Thyrostatic agents, such as thiamazole, do not influ-
ence the measurements (23).
Reproducibility studies yielded an interassay coefficient of var-
iation of 5% (n = 11) and an intraassay coefficient of variation
of 2% (n = 10) when a lyophilized urine specimen was exam-
ined for oxalate (mean value, 24 mg/1) with this test system.
(Tissue specimens even from the same glands do not guarantee
constant amounts of oxalate for reproducibility studies.)
To obtain accurate results, an internal standard (10 μΐ of a 12.5
g/1 oxalate solution) accompanied each sample. By measuring
the oxalate content of the sample with and without the internal
standard, a correction factor was determined separately for
each individual sample. The mean correction factor was found
to be 1.67 ± 0.71 (n = 97; range 0.70-3.27).
Statistics
Statistical methods applied in this study were Residual Analysis,
One-Way Analysis of Variance, Multiple Regression Analysis,
Least Significant Difference (LSD) (24) and the two-sample t
test for independent samples (25). The statistical packages
SPSS, version 3.1 (University of Washington, Seattle, USA)
and version 4.0 (University of T bingen, Germany), were used.
Residual Analysis of a model including the seven diagnostic
groups (cf. tab. 1) as a dummy independent variable, oxalate
concentration (in mg/kg dry substance) as the dependent vari-
able, and age and sex as possible sources of variation suggested
that the relationship is of exponential nature. Therefore, it was
thought appropriate to transform the oxalate concentrations
obtained into decadic logarithms for the statistical analyses.
Results
The mean oxalate content in fixed thyroid tissue from
autopsies (n = 40) was 880 ± 1530 mg/kg dry sub-
stance and the mean oxalate concentration for unfixed
thyroid tissue from autopsies was 131Q + 1770 mg/
kg dry substance (n = 63). The difference between
the unfixed and fixed samples was not statistically
significant (t = 1.24; p > 0.05). However, oxalate de-
termination in the supernatants of the unfixed samples
(n = 24) treated with protease and nuclease revealed
Varying amounts of oxalate (range approx. 100 — 600
mg/kg dry substance) especially in those supernatants
containing pepsin, papain and pronase E. This is
probably due to the fact that these glands were not
pretreated with CaCl2-ethanol. No oxalate was found
in the supernatants of fixed glands (n = 19), so these
supernatants could be discarded without oxalate loss.
For the unfixed thyroid glands, a loss of oxalate
during the enzymatic treatment therefore has to be
taken into account and may cast doubt upon the
statistical non-significance between the two groups.
The loss of oxalate was not pursued individually. The
mean water content of the unfixed thyroid glands
from the autopsies was 0.726 + 0.032 g/g fresh sub-
stance (n = 52) or 72.6%.
Table 1 shows the mean oxalate concentration of the
fixed thyroid tissue (surgical specimens) and the av-
erage age of the seven diagnostic groups. Figure 1
illustrates the difference in mean oxalate values be-
tween women and men.
Tab. 1. Mean oxalate concentration in thyroid tissue in mg/kg
dry substance in different histo-scintigraphical diag-
nostic groups: 1 = Diffuse colloid goitre, 2 = Partially
diffuse, partially nodular colloid goitre, 3 = Nodular
colloid goitre, 4 = Goitre with multifocal functional
autonomy, 5 = Non-functioning adenoma, 6 = Uni-
focal functional autonomy, 7 = Graves' disease;




























































One-way Analysis of Variance yielded F = 2.21 and
p = 0.048 for the logarithms of the mean oxalate
values of the seven diagnostic groups. This indicates
that the differences between the diagnostic groups
were barely statistically significant.
Multiple Regression Analysis revealed that the differ-
ences in oxalate concentration between the diagnostic
groups were not only due to different pathological
states, but also to differences in age and gender dis-
tribution as well as other possible sources of variation
which were not taken into account.
The relationship between diagnostic groups and age
did not change with age, i. e., there was no significant
interaction (24) between the two variables (p = 0.32).
The LSD test was used to compare the logarithmic
means of the oxalate concentrations of the seven
diagnostic groups. It showed that diagnostic groups
3 — 6 were statistically different from group 7 (Graves'
disease) at a significance level of 0.05.
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Diffuse colloid goitre
Partially diffuse, partially nodular goitre
Nodular colloid goitre
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Fig. 1 . Mean oxalate content (x-axis) of the seven diagnostic groups used (y-axis) in women and men.
Four groups with increasing crystal population den-
sity were examined microscopically, using approxi-
mately five high-power fields of vision of haematox-
ylin and eosin stained slides (400-fold enlargement)
under polarized light. It was shown that there is a
direct proportional relationship between the number
of birefringent calcium oxalate crystals and the
amount of oxalate measured with the enzymatic assay
(results not shown here). Particularly remarkable is
the extremely small number of oxalate crystals found
microscopically in thyroid glands of Graves' patients.
This fact is in agreement with the low oxalate con-
centration found in Graves' thyroid glands (fig. 1).
Discussion
For the determination of oxalate in the thyroid gland,
both fixed and unfixed tissue is suitable if the for-
maldehyde in the fixed samples is removed before
further processing. In unfixed specimens not pre-
treated with CaCl2-ethanol, however, the oxalate de-
termination is influenced by the loss of varying and
measurable amounts of oxalate during the enzymatic
treatment. As a general rule, unfixed thyroid glands
should therefore also be pretreated with CaCl2-etha-
nol. Oxalate determination in each of the several
supernatants produced during enzymatic digestion
would complicate the oxalate determination. A pos-
sible inhibiting influence of traces of formaldehyde
and other not identified inhibitors remaining in the
tissue can be excluded by using an internal standard
to determine a correction factor for each individual
sample.
The technique of formaldehyde extraction with cal-
cium chloride in absolute ethanol described above
allows the omission of a time-consuming lyophiliza-
tion procedure. As calcium chloride forms an insol-
uble complex of calcium with oxalate, oxalate is not
lost during this procedure. The presence of calcium
chloride also decreases the solubility of calcium oxa-
late by a 'common ion effect'. The solubility of cal-
cium oxalate in aqueous solutions is also decreased
by the presence of ethanol (1). The treatment with
proteases is thought to be superior to ultrafiltration
with subsequent acidification of the specimens (26).
With the latter technique, only soluble oxalate is
available for measurement, whereas insoluble calcium
oxalate crystals are lost.
In blood, plasma, plasma ultrafiltrate and urine the
measurement of oxalate is complicated by the fact
that glyoxalate and especially ascorbate gradually
convert to oxalate noii-enzymatically at pH > 4 even
at -20 °C (27-30). Kasidas & Rose (27) prevented
the in vitro generation of oxalate from L-ascorbic
acid by acidification and treatment with sodium ni-
trite. Such a gradual increase of oxalate in vitro can-
not be excluded from our unfixed samples, but prob-
ably does not play a major role in our fixed tissue
specimens, because formaldehyde forms addition
products with L-ascorbic acid (31).'In our autopsy
specimens the mean oxalate content of the unfixed
tissues was higher than for the tissues fixed with
formaldehyde, but the difference was not statistically
significant. The unknown losses of oxalate in the
unfixed thyroid during the enzymatic treatment casts
doubt on the significance of this finding.
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It was noted that in all diagnostic groups the standard
deviation was quite large. This finding is probably
not due to the methods employed but rather to the
unequal distribution of oxalate crystals in the thyroid
tissue (17). This was confirmed by our own exami-
nations of histological slides of thyroid tissue under
polarized light (results not shown here). As calcium
is also not distributed equally in the thyroid gland
(32), the present findings are not surprising. On the
other hand, a high concentration of calcium does not
necessarily correspond to a high concentration of
oxalate, because calcium forms different salts in the
thyroid. In functionally autonomous goitres, low cal-
cium concentrations have previously been found (32),
in contrast to the high oxalate concentrations found
in the present study. In addition, the number of ox-
alate crystals found in the thyroid gland is also de-
pendent on age, as already described by Richter in
1940 (33) and confirmed by Schaefer & Rentzschke
(34). The amount of calcium in the thyroid gland also
increases with age (32).
The highest oxalate concentrations were found in
goitres with functional autonomy, the lowest with
Graves' disease. The latter finding is in agreement
with the observations made by Richter et al. (8), who
noted the oxalate crystals were absent in histological
slides of thyroid glands with Graves' disease. Schaefer
& Rentzschke (34) demonstrated a decreasing number
of crystals with an increasing degree of endocrine
activity measured by the height of the follicular epi-
thelium. The low oxalate concentration measured in
hyperthyroid glands of the Graves' disease type must
be a phenomenon specific to this immunogenic con-
dition, particularly since the highest oxalate levels
were found in non-immunqgenic hyperthyroid states
such as multifocal and unifocal functional autonomy.
Leukocytes involved in the production of antibodies
contain high concentrations of ascorbate (35). A high
oxalate content might therefore the expected in the
thyroid glands with Graves9 disease which are infil-
trated by lymphocytes, but remarkably this was not
the case. Maintenance of intracellular ascorbic acid is
a priority for lymphocytes (36). Therefore one might
suppose that lymphocytes infiltrating the thyroid act
as scavengers of thyroid ascorbate, because the as-
corbate concentration in blood and tissue is lowered
in thyrotoxicosis.
An important feature of immunological injuries also
includes glycosanjinoglycan depolymerization in the
connective tissue (37). This could possibly diminish
the nucleation process of oxalate formation and ex-
plain the low amounts of oxalate found in Graves1
thyroids. However, the differences in oxalate concen-
tration between the groups with hyperthyroid states,
namely the high amount of oxalate found in the group
with functional autonomy, could be due to age, as
this group had the oldest patients. Since Gross (38)
and Reith et al. (10) noted increased numbers of
calcium oxalate crystals in de Quervain's thyroiditis,
it is unlikely that the inflammatory process found in
Graves9 disease is a factor leading to the low oxalate
concentration. It is also unlikely that the low oxalate
content is a simple effect of enhanced blood flow in
Graves9 thyroids, because in nodules with functional
autonomy blood flow is also enhanced. Nor is there
a special preoperative treatment particularly for
Graves9 thyroid, which could influence oxalate con-
centration or determination. An effect of thiamazol
on the determination was excluded by Weber-Hall
(23).
Gross (38) and Reith et al. (10) also noted calcium
oxalate deposits not only within the thyroid follicles,
but also in the interstitium of thyroid glands with de
Quervairfs granulomatous thyroiditis. Since according
to Sommers & Meissner (39) an important feature of
this disease is the rupturing of the basement mem-
brane, the intrafollicular crystals could escape into
the interstitium and cause granulomatous reactions.
This would agree with the observations of Hassel-
bacher (40), who elicited tissue reactions by incubating
rabbit fibroblast cultures with calcium oxalate crys-
tals. A similar mechanism could play a role in func-
tional autonomy, where degenerative changes also
frequently occur. It is possible that oxalate deposits
in degeneratively altered tissue are mobilized only
with difficulty and hence accumulate with time. This
is in agreement with the observation of Richter (33)
and Schaefer et al. (34) that the number of birefringent
oxalate crystals increases with age.
Whether or not there is a direct relationship between
follicle size and the amount of oxalate is unkown.
There is, however, a relationship between citric acid
and follicle size, as demonstrated by Födisch et al.
(41).
Oxalate gains pathognomonic significance in the hu-
man organism with excessive oxalate intake, with
infection by oxalate-producing Aspergillus species,
with diseases of the ileum leading to hyperoxaluria,
with increased endogenous oxalate synthesis due to
different enzyme defects, or pyridoxine or thiamine
deficiency, and with chronic renal failure causing ox-
alate retention (1).
At present, the origin of calcium oxalate can only be
hypothesized. Oxalic acid production may result from
conversion of ascorbate to oxalate in situ. Oxalic acid
production, however, also may be a physiological
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process in the thyroid gland: calcium oxalate crystals
also appear in thyroid cell cultures if isolated porcine
thyrocytes are spread in the culture medium (42). This
could indicate that the thyroid gland is an important
source of oxalate production in vivo as well. The
mechanism of calcium oxalate crystal formation in
the thyroid gland may be different from that of cal-
cium oxalate nephrolithiasis, where a defective oxalate
transport has been proposed (43). Hackett & Khan
(20) found calcium oxalate crystals in the thyroid
gland in 4 out of 20 infants at autopsy. MacMahon
et al. (17) found that crystals are already present in
premature infants, whereas Reidtt al. (19) could not
confirm these results. MacMahon et al. (17) emphasize
that the number of crystals increases with age. In
addition, the occurrence of calcium oxalate is not
confined to the human thyroid, but is also found in
the thyroid glands of other mammalian species (44).
Since ascorbic acid has been suggested to play a
physiological role in the regulation of iodination re-
actions in the thyroid (45) and is involved in the
synthesis of collagen (37) which plays a key role in
the maintenance of structural integrity, calcium oxa-
late may be a metabolite of ascorbate metabolism.
Calcium oxalate may also control the intracellular
calcium metabolism of the thyroid cells. A controlling
function at the level of enzymatic activity is also
conceivable, as oxalate can inhibit several enzymes
such as succinate dehydrogenase, alkaline and acid
phosphatases and lactate dehydrogenase (46). Gly-
colic acid oxidase does not seem to be present in the
human thyroid gland, however (19).
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